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Abstract
Hb Mizuho is a very rare unstable hemoglobin; here, we describe the clinical history of three Swiss family members with Hb
Mizuho together with a systematic review of the previously six published cases. The clinical history of the adult woman we report
here is unique since this is the first Hb Mizuho presenting with Moyamoya complications and the first case reported with long-
term erythrocyte exchange. The literature review showed that Hb Mizuho was mainly reported as a de novo mutation, with the
exception of children descended from known cases. All published patients with this unstable hemoglobin showed severe
hemolytic anemia with the exception of one; all were regularly transfused. Patients with higher HbF levels might require fewer
transfusions. All patients underwent splenectomy at a median age of 4 years and had variable clinical improvement; some
achieved complete resolution of transfusion dependency after splenectomy. Iron overload in Hb Mizuho patients seems to be
mainly attributed to transfusions and has less to do with ineffective erythropoiesis. Diagnosis might be challenging; a normal
hemoglobin electrophoresis should not rule out the diagnosis of unstable hemoglobin in patients with otherwise unexplained
hemolytic anemia. This series shows the enormous utility of using molecular techniques for diagnosis.
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Introduction
Hemoglobin (Hb) Mizuho is a very rare hemoglobinopathy
associated with congenital chronic hemolysis. Only six cases
have been reported worldwide to date. A heterozygous T→C
mutation at position 68 of the β-chain with a Leu→Pro sub-
stitution causes a severely unstable hemoglobin and is clini-
cally characterized by hemolytic anemia often leading to
transfusion dependency. Here, we report Hb Mizuho in three
members of a Swiss family, a currently 41-year-old Swiss
woman and her two children.
Case description
Case 1
The patient was born full term in 1979, after an uncomplicated
pregnancy and delivery with a birth weight of 2.88 kg. Her
hemoglobin levels dropped quickly to a level of 75 g/l within
the first 2 months of life. Fetal hemoglobin (HbF) and adult
hemoglobin A2 (HbA2) levels were at this point 1.8% and
2.9% respectively. The clinical presentation was interpreted
as severe coombs negative hemolytic anemia of unknown
etiology. Isopropanol test and erythrocyte enzymes were nor-
mal. Regular transfusion therapy was initiated at the age of 2
months, and she was henceforth transfusion-dependent with
an average requirement of two transfusions per month during
her first 3 years of life. She underwent splenectomy at the age
of 3, which contrary to the expected effect did not halt trans-
fusion dependency. Iron chelation therapy was initiated at age
15 with ferritin levels in the range of 7000 μg /l and has been
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continued with few interruptions up to date. Transfusion-
related alloimmunization has never occurred.
In the peripheral blood smear, remarkable basophilic stip-
pling, Heinz bodies, and reticulocytosis were evident (Fig. 1).
A bone marrow examination initially carried out at the age of
2 revealed hypercellularity for age with prominent erythroid
proliferation. A bonemarrow examination repeated later at the
age of 22, mainly due to persistent neutrophilia and lympho-
cytosis, showed similar findings. Conventional karyotyping
was normal.
When the patient was 23 years old, a new investigation for
her hemolytic anemia was initiated. Her initial hemoglobin
electrophoresis had yielded normal results. Blood samples
had to be delivered to a different hospital, meaning that dena-
turing of the unstable hemoglobin may have occurred before
testing. The presence of an unstable hemoglobin was first
detected when the test was performed immediately after blood
withdrawal, directly in the laboratory. An anomalous hemo-
globin was identified running before HbA2. Subsequent DNA
analysis of the beta-globin gene revealed a mutation in one of
the two alleles at codon 68 leading to a change from leucine
(CTC) to proline (CCC).
At the age of 25, therapy with hydroxyurea at a dose of
2000 mg daily was initiated and administered for a total of 33
months; her Hb F levels however did not increase (remained
in the range of 2 to 3%), and the therapy was therefore
discontinued. Transfusions of two red cell concentrates were
still required monthly.
At the age of 25, the patient presented with aphasia and
right-sided hemiparesis. Moyamoya, a disease characterized
by occlusion of cerebral vessels with development of collat-
eral vessels, in this case bilateral internal carotid artery steno-
sis, was diagnosed (Fig. 2). A surgical bypass revasculariza-
tion was performed without complications, and following sur-
gery, 100 mg aspirin was prescribed and is currently ongoing.
Since the most probable cause for the cerebrovascular com-
plication was the underlying hemoglobinopathy, a re-
assessment of the therapy was warranted. Red blood cell ex-
change apheresis every 6 weeks was therefore initiated at the
age of 25 and has been ongoing and generally well tolerated
up to date. Cholecystectomy was performed due to symptom-
atic cholelithiasis at the age of 26.
Her first pregnancy at the age of 24 was uneventful without
significant aggravation of hemolysis. Regular transfusions
were continued throughout the pregnancy, while iron chela-
tion was put on hold. During her second pregnancy at the age
of 30, red blood exchange apheresis was continued monthly.
The patient was able to complete her primary and second-
ary education and thereafter trained as a professional chef. She
currently receives partial disability pension due to the compli-
cations of her disease and works part time. She describes good
quality of life without relevant restrictions in her daily
activities.
Her two children were diagnosed with Hb Mizuho in early
infancy. Her eldest child is now 17 years old and currently
does not require regular transfusions. Her now 10-year-old
son requires transfusions every 6 to 12 weeks.
Case 2: her daughter
This is a 17-year-old female patient. She was born by C-
section due to breech positioning at a birth weight of 2.2 kg
and Apgar score of 8/9/9. Her hemoglobin level 2 days after
birth was 204 g/l. This decreased significantly to 57 g/l with
274 G/l reticulocytosis (13%) at the age of 7 months. Regular
transfusion therapy every 2 to 7 weeks was subsequently ini-
tiated. HbF level at the age of 4 years was 1.4%. DNA se-
quence analysis of the beta-globin gene revealed the same
mutation as in her mother. Iron chelation therapy with
deferasirox was begun at the age of 5 having ferritin levels
of 3400 μg/l. Despite elective splenectomy at the age of 7,
transfusions every 8 weeks were still required. During follow-
up, it was possible to prolong the transfusion intervals from
monthly to roughly once every 8 months. Cholecystectomy
Fig. 1 Peripheral blood smear of
case 1 using Giemsa staining.
Remarkable signs of
dyserythropoiesis with basophilic
stippling. This blood smear was 7
weeks after the last red cell
exchange apheresis
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was performed due to symptomatic cholelithiasis at the age of
10. At the age of 12 as her transfusion dependency decreased,
deferasirox was discontinued. Her current hemoglobin levels
are in the range of 80–85 g/l with reticulocytes of 1200–2000
G/l (85%) (Fig. 3), and her ferritin values remain in the normal
range of 60–70 μg/l. She also depicts high lactate dehydroge-
nase (LDH) levels of 1200–1400 U/L and total bilirubin levels
in the range of 60 μmol/l as well as an undetectable haptoglo-
bin. She is an active teenager, interested in sports and dance,
and describes a normal quality of life.
Case 3: her son
This is a 10-year-old boy who currently requires transfusions
every 6 to 12 weeks. Due to preterm labor at 37 weeks, he was
born via C-section with a birth weight of 2.3 kg and Apgar score
of 9/9/9. Regular transfusions every 4 to 6 weeks via port cath-
eter were first initiated at the age of 4 months, after his
hemoglobin levels dropped below 75 g/l. At 3 years of age,
ferritin levels reached 1552 μg/L; iron chelation therapy with
deferasirox was begun at a dose of 250 mg/d (= 18 mg/kg); this
has beenwell tolerated up to date. His current ferritin values have
consistently been below 500 μg/l, and therefore deferasirox has
been discontinued. In an effort to decrease transfusion dependen-
cy and iron overload, a partial splenectomywas performed at the
age of 6. A noticeable decrease of transfusion requirement from
once every 6 to 12weeks has been observed during the course of
time; the transfusion threshold was set at a hemoglobin value of
80 g/l. He is currently doing well in 3rd grade at primary school.
Both children have repeatedly been screened for
Moyamoya disease by magnetic resonance angiography with
negative results.
Due to the scarce information available on this unusual
hemoglobinopathy, we aimed to review all the cases in order
to delineate the most relevant characteristics of the published
cases to date (Table 1).
Fig. 2 MRI angiography of case
1 showing bilateral internal
carotid artery stenosis leading to
Moyamoya diagnosis. This was
prior to surgical revascularization
Fig. 3 Peripheral blood smear of
case 2. Methylene blue staining
showing reticulocytosis and some



































































































































































































































































































































































































































































































































































































































































































































HbMizuho is very rare. To our knowledge, only 6 cases have
been reported in the literature [1–6], with only one adult pa-
tient. HbMizuho was first reported in a Japanese girl (1), next
in an Italian girl (2), and later in boys from USA (3) and the
Netherlands (4). Hb Mizuho has recently been identified in
two family members from Sri Lanka (5). Hb Mizuho was
mainly reported as a de novo mutation, with the exception
of the two children reported here and the Sri Lankan boy.
Here, we describe the courses of three Swiss family mem-
bers with HbMizuho with transfusion dependency since early
infancy due to macrocytic, normochromic anemia with severe
chronic hemolysis. Interestingly, splenectomy did not lead to
resolution of transfusion dependency in any of them. Removal
of the spleen ideally prolongs red blood cell survival by re-
ducing red blood cell sequestration and may ultimately result
in the reduced need for blood transfusions. Splenectomy has
been shown to reduce transfusion requirements in patients
with thalassemia [7, 8] as well as sickle cell disease [9]. In
unstable hemoglobins, splenectomy should be considered
when there is severe anemia and/or massive or symptomatic
splenomegaly [10]. In the mother, there was practically no
change in transfusion requirement post-splenectomy; the chil-
dren however have profited mildly.
Variants of unstable hemoglobin represent a diagnostic
challenge in rare cases of congenital hemolytic anemia. The
lack of previous family history can guide the diagnosis in the
wrong direction and delay the diagnosis. Easier access to mo-
lecular tests has greatly facilitated diagnosis in recent years.
The first of our three cases clearly illustrates this difficulty
prior to easy access to molecular diagnosis. Despite the fact
that hemolysis was detected right after birth, several rounds of
diagnostic work-up remained unsuccessful with a confirmed
diagnosis only at the age of 23 years. This was only possible
with analysis of fresh blood, sampled directly in the
laboratory.
The clinical history of case 1 is unique since this is the first
HbMizuho presenting withMoyamoya complications and the
first case reported with long-term erythrocyte exchange.
Moyamoya disease is a very rare disorder characterized by
progressive stenosis and occlusion of the internal carotid ar-
teries and arteries of the circle ofWillis and its major branches.
Suzuki and Takaku introduced the term “Moyamoya disease”
to describe the numerous collateral vessels at the base, which
resembled a “puff of smoke” [11–13]. A single etiologic agent
has not been identified, although toxic, infectious, and inflam-
matory etiologies have been proposed, but never proven [14].
Moyamoya disease has previously been associated with sickle
cell disease [15]. Moyamoya has also been associated with
other hemolytic anemias including hemoglobin E-beta thalas-
semia as well as the rare hemoglobin Fairfax with beta-
thalassemia and Southampton hemoglobinopathy [16–19].
Putting all this into consideration, a correlation between
Moyamoya and HbMizuho in our case is, though not proven,
likely.
Furthermore, patients with chronic hemolytic anemia are
known to be at a higher risk of thrombotic complications
suggestive of a hypercoagulable state, the mechanism of co-
agulation activation likely being of multifactorial origin [20].
Regarding the association of Hb Mizuho and thrombosis, we
have not found other cases with thrombosis reported in the
literature. It must be emphasized that the patient presented
here developed Moyamoya disease at the age of 25. Since
elevated free plasma hemoglobin caused by hemolysis is toxic
for the vascular endothelium, this is a probable cause for the
vasoocclusive events in our patient.
This case suggests that patients with Hb Mizuho could be
at risk of thromboembolic complications and thrombosis pro-
phylaxis may be warranted in particular cases.
Our index patient has profited from red blood cell exchange
apheresis. Recurrent vasoocclusive events have since not oc-
curred, and her iron values are stable. Sufficiently repressing
the production of the harmful, aberrant hemoglobin could
therefore be considered beneficial as secondary prophylaxis
after a thromboembolic event. In red cell exchange, red blood
cells (RBCs) containing abnormal Hb are removed and re-
placed by healthy volunteer donor RBCs. Red cell exchange
can be performed by manual exchange or by automated ex-
change using a blood cell separator (erythrocytapheresis).
Compared to simple RBC transfusions, this procedure offers
several advantages, such as lower risk for iron accumulation
and efficient control of pathological erythrocyte populations.
The most frequent indication for RBC exchange is sickle cell
disease; this is the standard treatment in patients with a history
of or a risk for acute stroke and is a clinical option for other
acute complications of sickle cell disease [21].
In this case, the treatment with hydroxyurea did not bring
any clinical benefit; further conclusions are no possible due to
the lack of data in the literature reporting experiences using
hydroxyurea in this hemoglobinopathy.
Iron overload is of clinical relevance in many hemoglobin-
opathies. Iron overload develops from increased intestinal iron
absorption signaled by hepcidin suppression secondary to in-
effective erythropoiesis [22], while it can also be secondary to
regular transfusions. The degree of toxicity may also vary
depending on the disease.
Iron overload in Hb Mizuho patients seems to be mainly
attributed to transfusions and has less to do with ineffective
erythropoiesis. The degree of iron overload seems to present
itself with different patterns. The type and dosing of chelation
therapy should be adapted according to the individual’s
course. Both oral and intravenous iron chelators are effective.
Due to the scarce information available on this unusual
hemoglobinopathy, we aimed to review all the cases in order
to delineate the most relevant characteristics of the published
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cases to date. Thus, the patients described in the literature had
severe hemolytic anemia and with the exception of one; all
were regularly transfused (Table 1). Remarkable basophilic
stippling, Heinz bodies, and reticulocytosis seem to be a com-
mon feature in all these cases. All patients underwent splenec-
tomy at a median age of 4 years (range 3–7) and had variable
clinical improvement after splenectomy. One patient did rea-
sonably well until the age of 4 years (3) and was not transfu-
sion dependent even before splenectomy. Splenectomy in this
case, which was performed due gradually worsening anemia
(hemoglobin 72 g/l at the age of 4 years) and marked spleno-
megaly (spleen size 349 gr), improved his condition consid-
erably. Three patients achieved complete resolution of trans-
fusion dependency after splenectomy (cases 1, 2, and 4),
supporting the benefit of this procedure.
Hemoglobin F level seems to be helpful in the follow-up of
Hb Mizuho. A reported case with mild clinical presentation
had a large quantity of HbF up to the age of 5 years (HbF
levels of 35% and 22% at the ages of 2 and 4 respectively) (3).
The Dutch boy described by Harthoorn et.al. (4) similarly had
relatively high HbF levels, which could explain why transfu-
sion dependency began much later at the age of 2 years. In the
two of our patients, where HbF was measured, levels were
normal, nicely explaining transfusion dependency in these
patients.
Information regarding the clinical courses of Hb Mizuho
patients through to adulthood is scarce. This forth reported
patient from the Netherlands was diagnosed with papillary
thyroid carcinoma, for which he was curatively treated with
a total thyroidectomy plus lymph node dissection and radio-
active iodine therapy at the age of 13 years. He later developed
fulminant hepatic failure requiring liver transplantation at the
age of 25 years. Interestingly, Gilbert syndrome was also di-
agnosed. The authors describe a possible connection between
the hemoglobinopathy and the liver disease, as it is known in
intrahepatic cholestasis of sickle cell disease [6].
A normal hemoglobin electrophoresis should not rule out
the diagnosis of unstable hemoglobin in patients with other-
wise unexplained hemolytic anemia, since unstable hemoglo-
bin variants that undergo rapid denaturation or are represented
in the HbA fraction might not be detected by this method [23].
This could lead to under- or misdiagnosis. Though repeat
testing should be encouraged in unclear cases, this series
shows the enormous utility of using molecular techniques
for diagnosis. The numerous tests initially performed in our
reported cases, including isopropanol stability tests, erythro-
cyte fragility tests, heat denaturation test, high performance
liquid chromatography, and hemoglobin electrophoresis, did
not yield conclusive results. Examination of hemoglobin sta-
bility by heat or isopropanol is a useful screening test in de-
tection of unstable hemoglobins. Stability testing is performed
by incubating with isopropanol, whereby unstable hemoglo-
bins yield visible precipitates. Similarly, in heat stability
testing, hemolysate is incubated for 1–2 h at 50 °C. Unstable
hemoglobins yield a visible precipitate, while normal hemo-
globins do not [24, 25]. Correcting pre-analytic errors in our
index patient however led to the diagnosis. With this excep-
tion, identification of the variant required sequencing of a
segment of amplified DNA that included the beta-globin gene.
Bonemarrow examinations did not contribute to the diagnosis
either. The only relevant finding in the five cases where bone
marrow examination was performed was erythroid
hyperplasia.
It must be highlighted that the first Hb Mizuho case was
reported in 1977 with the following 3 cases reported in the
early 1990s. The algorithm for hemoglobinopathy testing has
since evolved enormously [23]. Red cell indices and morphol-
ogy followed by separation and measurement of Hb fractions
using protein-based methods (Hb electrophoresis and high
performance liquid chromatography (HPLC)) are nowadays
the methods of choice for initial qualitative and quantitative
Hb analyses. Hb variants can usually be detected using these
methods. A survey done by van Zwieten et al. [26] involving
20,000 blood samples showed that high performance liquid
chromatography analysis followed by globin gene sequencing
of rare variants is an effective method to reveal Hb variants.
DNA-based methods are used as the following step for vari-
ants with ambiguous or unusual results from protein analysis.
Cappellini et al. [27] illustrate the recommended diagnostic
flowchart for identification of thalassemia, which can be ap-
plied for suspected Hb variants.
Molecular diagnostic possibilities have grown enormously
in the past decades. This paper aims to raise awareness that
rarer and not necessarily inherited diseases can nowadays eas-
ily be diagnosed.
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